Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients.

Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients.

AIMS: Current screening methods, such as single strand conformational polymorphism (SSCP) and denaturing high performance liquid chromatography (dHPLC) that are used for detecting mutations in familial hypercholesterolaemia (FH) subjects are time consuming, costly and only 80-90% sensitive. Here we...

Podrobná bibliografie
Hlavní autoři:	Whittall, R, Scartezini, M, Li, K, Hubbart, C, Reiner, Z, Abraha, A, Neil, H, Dedoussis, G, Humphries, SE
Médium:	Journal article
Jazyk:	English
Vydáno:	2010

Podobné jednotky

Statins and familial hypercholesterolaemia.
Autor: Neil, A, a další
Vydáno: (2009)

DEVELOPMENT OF AN AFFORDABLE, SENSITIVE AND RAPID SCREENING METHOD FOR MUTATION DETECTION IN UK FH SUBJECTS
Autor: Scartezini, M, a další
Vydáno: (2008)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
Autor: Minhas, R, a další
Vydáno: (2009)

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.
Autor: Humphries, SE, a další
Vydáno: (2006)

Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic
Autor: Futema, M, a další
Vydáno: (2013)

Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.
Autor: Futema, M, a další
Vydáno: (2013)

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
Autor: Humphries, SE, a další
Vydáno: (2005)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Autor: Marks, D, a další
Vydáno: (2000)

The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Autor: Scartezini, M, a další
Vydáno: (2007)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
Autor: Marks, D, a další
Vydáno: (2003)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Autor: Marks, a další
Vydáno: (2000-01-01)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
Autor: Futema, M, a další
Vydáno: (2014)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
Autor: Neil, H, a další
Vydáno: (2000)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
Autor: Marks, D, a další
Vydáno: (2002)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
Autor: Marks, D, a další
Vydáno: (2006)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
Autor: Neil, H, a další
Vydáno: (2004)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
Autor: Marks, D, a další
Vydáno: (2003)

Familial hypercholesterolaemia.
Autor: Gill, P, a další
Vydáno: (2012)

Familial hypercholesterolaemia
Autor: D.J. Blom
Vydáno: (2011-01-01)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Autor: Neil, H, a další
Vydáno: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
Autor: Neil, H, a další
Vydáno: (2004)

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Autor: Nherera, L, a další
Vydáno: (2010)

Cardiovascular Disease Risk Estimation in Mutation Confirmed Familial Hypercholesterolaemia
Autor: E. Ofagbor, a další
Vydáno: (2023-12-01)

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study
Autor: Talmud, P, a další
Vydáno: (2013)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
Autor: Seed, M, a další
Vydáno: (2011)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Autor: Neil, A, a další
Vydáno: (2003)

EASILY MISSED? Familial hypercholesterolaemia
Autor: Gill, P, a další
Vydáno: (2012)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
Autor: Neil, H, a další
Vydáno: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
Autor: Neil, H, a další
Vydáno: (2005)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Autor: Seed, M, a další
Vydáno: (2009)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Autor: Seed, M, a další
Vydáno: (2009)

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
Autor: Talmud, P, a další
Vydáno: (2013)

How many individuals with Familial Hypercholesterolaemia (FH) need to be identified to achieve the NHS 2019 Long Term Plan ambition?
Autor: S.E. Humphries, a další
Vydáno: (2023-12-01)

Familial Hypercholesterolaemia: An Updated Overall Management
Autor: Mohd Kasim, Noor Alicezah, a další
Vydáno: (2020)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
Autor: Neil, A, a další
Vydáno: (2008)

Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Autor: Vallejo-Vaz, Antonio J., a další
Vydáno: (2020)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
Autor: J. Gratton, a další
Vydáno: (2022-10-01)

Simplifying the detection of <it>MUTYH </it>mutations by high resolution melting analysis
Autor: López-Villar Isabel, a další
Vydáno: (2010-08-01)

Identification of FH-causing variants in patients with clinical familial hypercholesterolaemia recruited into the 100,000 genome project: preliminary analysis
Autor: A. Rimbert, a další
Vydáno: (2021-09-01)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
Autor: J. Gratton, a další
Vydáno: (2023-12-01)